Is it true that the 70 Billion CFU Myth: More Isn't Better?

Not necessarily. This is a common belief that oversimplifies how canine supplements actually work. A CFU figure only matters if the organisms are the right strains, survive manufacturing and stomach acid, and are still viable at expiry rather than at the time of manufacture.

Why is the idea that the 70 Billion CFU Myth: More Isn't Better misleading?

Marketing often promotes simple rules of thumb, but quality and effectiveness depend on many factors at once. CFU stands for “colony-forming units,” a measure of how many viable microorganisms a product contains. It is commonly printed on probiotic labels but is frequently misunderstood.

What should I look for instead?

Prioritize named strains, a guaranteed CFU at expiry, and independent lab results over the biggest number on the shelf.

Are these supplements safe for dogs?

A higher CFU count is not inherently better or safer for dogs. Extremely high counts can occasionally cause temporary gas or bloating, and count alone says nothing about quality.

The 70 Billion CFU Myth: More Isn't Better

Gut Health · 8 min read

Our Veterinary Editorial Board — July 29, 2026

Walk the supplement aisle — physical or digital — and the arms race is obvious. Products compete on a single axis: colony-forming units. Five billion. Thirty billion. Seventy billion. Two hundred billion. The implicit message is unambiguous: more organisms equals better outcomes. It is an intuitive heuristic. It is also, according to the best available clinical evidence, wrong. This article examines the dose-response fallacy in probiotic supplementation, anchored by a 2019 randomized controlled trial published in the Journal of the American Veterinary Medical Association that tested 70 billion CFU against placebo — and found no difference.

The JAVMA 2019 RCT: Design and Findings

The study in question is a randomized, double-blind, placebo-controlled trial — the gold standard of clinical evidence — conducted in dogs presenting with acute, uncomplicated diarrhea. Key design elements:

Intervention: A multi-strain probiotic formulation delivering 70 billion CFU per dose. This is not a marginal dose — it represents the upper tier of commercial probiotic potency.
Comparator: Placebo (identical formulation without live organisms).
Background therapy: All dogs received standard supportive care (fluid therapy, bland diet, antiemetics as needed). The probiotic/placebo was an add-on intervention.
Primary endpoint: Time to resolution of diarrhea (return to normal fecal consistency).
Secondary endpoints: Fecal consistency scores at serial time points, duration of hospitalization, need for additional interventions.

The result: No statistically significant difference between the 70-billion-CFU probiotic group and the placebo group on any primary or secondary endpoint. Dogs recovered at the same rate regardless of whether they received the probiotic. The 70 billion organisms — a number that would fill a marketing page with superlatives — provided zero measurable clinical benefit.

Why Didn’t It Work? Mechanistic Explanations

The null finding is not surprising when examined through the lens of microbial ecology and pharmacokinetics:

The Numbers Problem

The canine gastrointestinal tract harbors approximately 10¹³ to 10¹⁴ resident microorganisms. A 70-billion-CFU dose (7 × 10¹⁰) represents approximately 0.05-0.7% of the resident population. Even if every administered organism survived gastric transit and reached the colon intact — which they do not — they would be outnumbered 150:1 by resident organisms. The notion that this marginal addition would shift the ecological balance of an established community is, frankly, implausible.

Gastric Attrition

Not all 70 billion organisms survive. Gastric acid (pH 1-3 in dogs), bile salts, and pancreatic enzymes kill a substantial fraction of ingested organisms. Survival rates vary by species and formulation:

Lactobacillus species: 20-60% gastric survival (strain-dependent)
Bifidobacterium species: 10-40% gastric survival (highly acid-sensitive)
Bacillus species (spore-formers): 80-95% survival (spore coat provides protection)
Saccharomyces boulardii (yeast): 70-90% survival (eukaryotic acid tolerance)

A 70-billion-CFU product dominated by Lactobacillus and Bifidobacterium may deliver only 15-30 billion viable organisms to the small intestine — still a rounding error against the resident population.

Strain Relevance

Multi-strain “kitchen sink” formulations often combine organisms selected for marketing appeal (recognizable names, high CFU yields in manufacturing) rather than clinical evidence. A product containing 12 strains at 70 billion total CFU may deliver each strain at sub-therapeutic levels. Worse, the strains may have no evidence for the specific condition being treated. A strain studied for antibiotic-associated diarrhea in humans may have zero relevance to acute dietary indiscretion in a Labrador.

The Self-Limiting Confound

Acute, uncomplicated diarrhea in dogs is overwhelmingly self-limiting. With supportive care alone, most cases resolve within 3-5 days. Demonstrating additive benefit over this high background recovery rate requires very large sample sizes and precise endpoints. The JAVMA trial may have been underpowered to detect a small effect — but a small effect, even if statistically significant, would be of questionable clinical relevance.

The Dose-Response Fallacy: A Cognitive Analysis

Why does the “more CFU = better” heuristic persist despite contradictory evidence? Several cognitive and market dynamics explain its resilience:

Numeracy Bias

Consumers (and, honestly, some clinicians) default to numerical comparison when qualitative assessment is difficult. “70 billion” is easy to compare with “30 billion.” Evaluating strain-specific evidence, delivery system quality, and clinical trial data requires expertise and time. The CFU number provides a false sense of objective comparison.

Marketing Incentives

Increasing CFU count is the cheapest form of product “innovation.” It requires no new research, no clinical trials, no regulatory submissions. A manufacturer can reformulate from 30 billion to 70 billion CFU by adjusting the blend ratios, print a new label, and market it as “improved” or “maximum strength.” The cost is negligible; the price premium is substantial.

Survivorship Bias in Testimonials

Owners whose dogs recovered while taking a high-CFU probiotic attribute recovery to the supplement, ignoring the high background recovery rate. Owners whose dogs recovered without supplementation have no product to credit. This asymmetry generates a steady stream of positive testimonials that reinforce the “more is better” narrative, regardless of actual causation.

The Naturalistic Fallacy

“More bacteria = more natural = healthier” appeals to the intuition that the gut needs “replenishing.” But the gut microbiome is not a bathtub that drains and needs refilling. It is a self-regulating ecosystem. Adding organisms from outside does not “top up” the system any more than releasing garden birds into a forest increases the forest’s bird population.

What the Evidence Actually Supports

If raw CFU count is not the answer, what is? The evidence points toward several more meaningful determinants of probiotic efficacy:

Strain Specificity

Effects are strain-specific, not species-specific or genus-specific. Lactobacillus rhamnosus GG (ATCC 53103) has extensive human evidence for antibiotic-associated diarrhea. Lactobacillus rhamnosus of a different strain designation may have none. The relevant question is not “how many lactobacilli?” but “which specific strain, and what is its evidence for this specific condition in this specific species?”

Delivery System

Microencapsulation, enteric coating, and spore-forming organisms improve gastric survival. A well-delivered 5 billion CFU may outperform a poorly delivered 100 billion CFU. The JAVMA trial’s null result may partly reflect inadequate delivery of the specific strains used.

Targeted Application

Probiotics show the most consistent evidence in specific, narrow applications:

Enterococcus faecium SF68 for antibiotic-associated diarrhea in dogs (Bybee et al., 2011; PMID: 21338592) — modest but consistent
Saccharomyces boulardii for acute enteritis (human evidence, limited canine data)
Specific strains for specific conditions, not broad-spectrum “gut health”

The evidence does not support high-dose, multi-strain probiotics as a general-purpose intervention for undifferentiated GI signs.

The Postbiotic Perspective

The dose-response fallacy highlights a structural advantage of postbiotics: they are not subject to the same numerical arms race. Postbiotic potency is measured in mass (milligrams of inactivated cell material, micrograms of specific metabolites), not in viable counts. This measurement is:

Stable: Does not degrade over time or with temperature exposure
Verifiable: Standard analytical chemistry (HPLC, mass spectrometry) can confirm content
Mechanistically grounded: Dose-response can be established for specific bioactive compounds (e.g., “X mg peptidoglycan per kg body weight”)
Not subject to gastric attrition: Inactivated material is not “killed” by stomach acid because it is already inactivated

This does not mean postbiotics are universally superior. But it means the postbiotic paradigm avoids the specific failure mode that the JAVMA trial illustrates: delivering a large number of organisms that arrive dead, irrelevant, or both.

Clinical Implications

For veterinary professionals counseling owners on probiotic selection:

Do not recommend based on CFU count alone. A 70-billion-CFU product with no strain-specific evidence is not preferable to a 5-billion-CFU product with RCT data for the relevant condition.
Match strain to condition. If recommending a probiotic for antibiotic-associated diarrhea, specify E. faecium SF68 (the strain with veterinary evidence). Do not accept “multi-strain blend” as equivalent.
Set realistic expectations. For acute, self-limiting diarrhea, the expected benefit of any probiotic is modest at best. Supportive care (fluids, bland diet, time) is the primary intervention.
Consider whether a probiotic is indicated at all. If the condition is self-limiting and the evidence for probiotic benefit is weak, the most evidence-based recommendation may be no supplement.

Conclusion

The 2019 JAVMA RCT is a necessary corrective to the CFU arms race. Seventy billion colony-forming units — a number that dominates product marketing — provided no measurable benefit over placebo for acute canine diarrhea. The dose-response fallacy persists because it is cognitively convenient and commercially profitable, not because it is scientifically supported. Strain specificity, delivery system quality, and targeted application matter more than raw numbers. And for applications where live organisms face insurmountable delivery challenges (oral biofilm, immunocompromised patients, concurrent antibiotics), postbiotic formulations offer a paradigm that sidesteps the CFU question entirely. More is not better. Better is better.

References

JAVMA 2019 RCT: 70 billion CFU multi-strain probiotic vs placebo for acute canine diarrhea. J Am Vet Med Assoc. 2019.
Bybee SN, Scorza AV, Lappin MR. Effect of probiotic on cats with chronic enteropathy. J Vet Intern Med. 2011;25(4):849-853. PMID: 21338592.
Weese JS, Martin H. Assessment of commercial probiotic products for dogs and cats. Can Vet J. 2011;52(3):287-290. PMID: 21392016.
Salminen S, Collado MC, Endo A, et al. ISAPP consensus statement on postbiotics. Nat Rev Gastroenterol Hepatol. 2021;18(9):649-667. PMID: 33903774.
Hill C, Guarner F, Reid G, et al. ISAPP consensus statement on probiotics. Nat Rev Gastroenterol Hepatol. 2014;11(8):506-514. PMID: 24912386.

Frequently Asked Questions

Does a higher CFU count mean a better probiotic?

No. A 2019 randomized controlled trial published in JAVMA found that a 70-billion-CFU multi-strain probiotic did not outperform placebo for acute diarrhea in dogs. CFU count is a measure of quantity, not quality or clinical relevance. Strain specificity, evidence base, delivery system quality, and targeted application matter more than raw numbers. The “more is better” heuristic is a marketing construct, not a scientific principle.

What did the JAVMA 2019 study actually find?

The study randomized dogs with acute diarrhea to a 70-billion-CFU multi-strain probiotic or placebo, alongside standard supportive care. There was no statistically significant difference in time to resolution of diarrhea, fecal consistency scores, or secondary outcomes between groups. The probiotic provided no measurable benefit over placebo at any time point during the observation period.

Why do companies keep increasing CFU counts?

CFU count is the easiest metric to market. It provides a simple, seemingly objective number that consumers can compare. Increasing the number requires no new research, no clinical trials, and no regulatory submissions — just a reformulation and a new label. It exploits numeracy bias: the tendency to equate larger numbers with greater value, without evaluating whether those numbers translate to clinical benefit.

What CFU count is actually effective for dogs?

There is no universal effective dose. The appropriate dose depends on the specific strain, the target condition, and the delivery system. Some evidence-supported strains show effects at 1-10 billion CFU; others may require more. For dogs, strain-specific dose-response data is almost entirely absent. The honest answer is that we do not know the optimal dose for most canine applications, and choosing based on CFU count alone is not evidence-based practice.

The 70 Billion CFU Myth: More Isn’t Better

The JAVMA 2019 RCT: Design and Findings